Renaissance Technologies
URGN icon

Renaissance Technologies’s UroGen Pharma URGN Stock Holding History

Renaissance Technologies’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-244,300
Closed -$5.72M – 3708
2025
Q4 		$5.72M Sell
244,300
-30,800
-11% -$668K 0.01% 1218
2025
Q3 		$5.49M Buy
275,100
+236,900
+620% +$4.25M 0.01% 1435
2025
Q2 		$523K Sell
38,200
-52,400
-58% -$503K ﹤0.01% 2803
2025
Q1 		$1M Sell
90,600
-47,600
-34% -$507K ﹤0.01% 2432
2024
Q4 		$1.47M Buy
+138,200
New +$1.65M ﹤0.01% 2255
2024
Q1 		– Sell
-91,300
Closed -$1.37M – 4103
2023
Q4 		$1.37M Sell
91,300
-69,000
-43% -$896K ﹤0.01% 2200
2023
Q3 		$2.25M Buy
160,300
+86,300
+117% +$1.39M ﹤0.01% 1788
2023
Q2 		$766K Buy
74,000
+26,000
+54% +$287K ﹤0.01% 2635
2023
Q1 		$444K Buy
48,000
+4,700
+11% +$43.3K ﹤0.01% 2943
2022
Q4 		$384K Buy
43,300
+200
+0.5% +$1.89K ﹤0.01% 3105
2022
Q3 		$359K Sell
43,100
-500
-1% -$4.14K ﹤0.01% 3115
2022
Q2 		$357K Buy
43,600
+18,900
+77% +$130K ﹤0.01% 3354
2022
Q1 		$215K Buy
+24,700
New +$193K ﹤0.01% 3614
2021
Q1 		– Sell
-32,800
Closed -$591K – 3728
2020
Q4 		$591K Buy
+32,800
New +$687K ﹤0.01% 2745
2019
Q2 		– Sell
-8,000
Closed -$296K – 3767
2019
Q1 		$296K Buy
+8,000
New +$335K ﹤0.01% 3098
2018
Q4 		– Sell
-16,800
Closed -$793K – 3629
2018
Q3 		$793K Sell
16,800
-98,651
-85% -$4.58M ﹤0.01% 2697
2018
Q2 		$5.75M Sell
115,451
-41,249
-26% -$2.4M 0.01% 1699
2018
Q1 		$7.79M Buy
156,700
+25,600
+20% +$1.28M 0.01% 1530
2017
Q4 		$4.88M Buy
131,100
+105,500
+412% +$3.76M 0.01% 1824
2017
Q3 		$807K Buy
+25,600
New +$565K ﹤0.01% 2645

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Renaissance Technologies's URGN Position: Q1 2026 in Review

Renaissance Technologies sold out of UroGen Pharma (URGN) in Q1 2026, closing a stake of 244,300 shares — an estimated $5.72M sold.

Renaissance Technologies first reported a position in URGN in Q3 2017 and held it in 20 quarters. The position peaked at $7.79M in Q1 2018. 173 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

  • Renaissance Technologies reported no remaining UroGen Pharma position as of Q1 2026 after selling out during the quarter.
  • Renaissance Technologies sold 244,300 UroGen Pharma shares in Q1 2026, an estimated $5.72M.
  • Renaissance Technologies first reported a position in UroGen Pharma in Q3 2017 and held it in 20 quarters.
  • Renaissance Technologies's UroGen Pharma position peaked at $7.79M in Q1 2018.
  • 173 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.